JP2004523494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004523494A5 JP2004523494A5 JP2002547529A JP2002547529A JP2004523494A5 JP 2004523494 A5 JP2004523494 A5 JP 2004523494A5 JP 2002547529 A JP2002547529 A JP 2002547529A JP 2002547529 A JP2002547529 A JP 2002547529A JP 2004523494 A5 JP2004523494 A5 JP 2004523494A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- ganglioside
- treatment
- outer membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 101710019325 GDI2185 Proteins 0.000 claims 8
- 150000002270 gangliosides Chemical class 0.000 claims 8
- 241000588650 Neisseria meningitidis Species 0.000 claims 7
- 101700036978 OMP Proteins 0.000 claims 7
- 239000002671 adjuvant Substances 0.000 claims 7
- 230000000240 adjuvant Effects 0.000 claims 7
- 101700064522 eaeA Proteins 0.000 claims 7
- 229940052778 Neisseria meningitidis Drugs 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000038129 antigens Human genes 0.000 claims 4
- 108091007172 antigens Proteins 0.000 claims 4
- 239000003725 proteoliposome Substances 0.000 claims 4
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 3
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 229960005486 vaccines Drugs 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 206010004018 Bacterial infectious disease Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 210000000481 Breast Anatomy 0.000 claims 2
- 210000001072 Colon Anatomy 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 229940104302 Cytosine Drugs 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 210000003128 Head Anatomy 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 210000003739 Neck Anatomy 0.000 claims 2
- 210000001672 Ovary Anatomy 0.000 claims 2
- 210000002307 Prostate Anatomy 0.000 claims 2
- 208000001756 Virus Disease Diseases 0.000 claims 2
- 201000005216 brain cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000002458 infectious Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 229940080701 Chymosin Drugs 0.000 claims 1
- 108090000746 Chymosin Proteins 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 101700075868 HER1 Proteins 0.000 claims 1
- 108091007929 PDGF receptors Proteins 0.000 claims 1
- 230000001580 bacterial Effects 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 230000002209 hydrophobic Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108010030416 proteoliposomes Proteins 0.000 claims 1
Claims (23)
- (A) 1種類以上の低免疫原性抗原と、(B) グラム陰性菌株(Neisseria meningitidis)の外膜蛋白複合体から得られ、その中にガングリオシドが組み込まれているプロテオリポソームを有するワクチン担体と、(C) 場合によっては1種類以上のアジュバントとを含有する、免疫原性の低い抗原の免疫原性を増強するための医薬組成物。
- 該免疫原性の低い抗原が、ペプチド、ポリペプチド、蛋白若しくはこれらに対応する配列の核酸、またはワクチン対象たる標的細胞若しくはその溶解産物、あるいはこれらの組み合わせから選択される請求項1に記載の医薬組成物。
- 該免疫原性の低い抗原またはその細胞外ドメインが、増殖因子レセプターである請求項2に記載の医薬組成物。
- 該増殖因子レセプターの該細胞外ドメインが、膜貫通ドメインを含有する、または含有しない請求項3に記載の医薬組成物。
- 該増殖因子レセプターが、膜貫通ドメインを持つまたは持たない、HER-1、HER-2、PDGF-Rまたは細胞外ドメインを含有するあらゆる変異体である、請求項3および4に記載の医薬組成物。
- 該ワクチン担体のプロテオリポソームが、野生型のもしくは遺伝的に修飾したNeisseria meningitidis菌株の外膜蛋白複合体から得られる請求項1に記載の医薬組成物。
- その中にガングリオシドが組み込まれているワクチン担体のプロテオリポソームが、Neisseria meningitidisの外膜蛋白複合体中に当該ガングリオシドを疎水的に組み込ませることによって得られる請求項1に記載の医薬組成物。
- Neisseria meningitidisの外膜蛋白複合体中に疎水的に組み込まれている該ガングリオシドが、GM1、GM3またはこれらのN-グリコシル化変異体である、請求項7に記載の医薬組成物。
- 該アジュバントが、油性のアジュバント、または天然もしくは組換えポリペプチドである請求項1に記載の医薬組成物。
- 該油性のアジュバントが、フロイントの不完全アジュバントである請求項9に記載の医薬組成物。
- 該フロイントの不完全アジュバントが、Montanide ISA51である請求項10に記載の医薬組成物。
- 該ポリペプチドアジュバントが、シトシンまたはキモシンである請求項9に記載の医薬組成物。
- 該シトシンが、顆粒球−マクロファージコロニー刺激因子である請求項12に記載の医薬組成物。
- ガン、特に、前立腺、結腸、肺、乳房、卵巣、頭頸部、外陰、膀胱および脳のガン、神経膠腫、さらに非伝染性慢性疾患の予防と治療のための請求項1から13に記載の医薬組成物。
- ウイルス感染性疾患および細菌感染性疾患の予防と治療のための請求項1から13に記載の医薬組成物。
- 後天性免疫不全症候群の治療のための請求項14に記載の医薬組成物。
- 自己免疫疾患の治療のための請求項1から13に記載の医薬組成物。
- ガン、特に、前立腺、結腸、肺、乳房、卵巣、頭頸部、外陰、膀胱および脳のガン、神経膠腫、さらに非伝染性慢性疾患の予防と治療のために請求項1から17に記載の医薬組成物の使用。
- ウイルス感染性疾患および細菌感染性疾患の予防と治療のための請求項1から17に記載の医薬組成物の使用。
- 自己免疫疾患の治療のための請求項1から17に記載の医薬組成物の使用。
- 免疫抑制状態の患者において免疫を回復するための治療に使用する医薬品を製造するための、その中にガングリオシドが組み込まれたグラム陰性細菌菌株Neisseria meningitidisの外膜蛋白複合体(OMPC)から得られる極小サイズプロテオリポソーム(VSSP)の使用。
- その中にガングリオシドが組み込まれた該プロテオリポソームを、Neisseria meningitidisの外膜蛋白複合体に当該ガングリオシドを疎水的に組み込ませることによって得る請求項21に記載の使用。
- Neisseria meningitidisの外膜蛋白複合体に疎水的に組み込ませたガングリオシドが、GM1、GM3またはこれらのN-グリコシル化変異体である請求項22の使用。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20000285A CU23000A1 (es) | 2000-12-06 | 2000-12-06 | Composiciones vacunales para la inmunoterapia activa específica del cáncer |
CU20010167A CU23009A1 (es) | 2001-07-12 | 2001-07-12 | Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos |
CU167/2001 | 2001-07-12 | ||
PCT/CU2001/000010 WO2002045746A2 (es) | 2000-12-06 | 2001-12-06 | Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2004523494A JP2004523494A (ja) | 2004-08-05 |
JP2004523494A5 true JP2004523494A5 (ja) | 2005-05-26 |
JP2004523494A6 JP2004523494A6 (ja) | 2005-06-30 |
JP4210519B2 JP4210519B2 (ja) | 2009-01-21 |
Family
ID=38812545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002547529A Expired - Lifetime JP4210519B2 (ja) | 2000-12-06 | 2001-12-06 | 低免疫原性抗原の免疫原性を増強する医薬組成物 |
Country Status (20)
Country | Link |
---|---|
US (1) | US7776342B2 (ja) |
EP (1) | EP1356822B1 (ja) |
JP (1) | JP4210519B2 (ja) |
KR (1) | KR100850473B1 (ja) |
CN (1) | CN1291755C (ja) |
AR (1) | AR031638A1 (ja) |
AT (1) | ATE485833T1 (ja) |
AU (2) | AU2151902A (ja) |
BR (1) | BRPI0116013B8 (ja) |
CA (1) | CA2431188C (ja) |
DE (1) | DE60143363D1 (ja) |
DK (1) | DK1356822T3 (ja) |
EA (1) | EA005138B1 (ja) |
HK (1) | HK1063726A1 (ja) |
MX (1) | MXPA03005032A (ja) |
NZ (1) | NZ526282A (ja) |
PE (1) | PE20020572A1 (ja) |
UY (1) | UY27059A1 (ja) |
WO (1) | WO2002045746A2 (ja) |
ZA (1) | ZA200304411B (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1367395A1 (de) * | 2002-05-02 | 2003-12-03 | B.R.A.H.M.S Aktiengesellschaft | Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern |
EP1358910A1 (de) * | 2002-05-02 | 2003-11-05 | B.R.A.H.M.S Aktiengesellschaft | Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen |
CU23257A1 (es) * | 2003-02-27 | 2008-01-24 | Centro Inmunologia Molecular | COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA |
AR045815A1 (es) * | 2003-10-09 | 2005-11-16 | Ct Ingenieria Genetica Biotech | Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano |
WO2005111079A2 (en) * | 2004-05-14 | 2005-11-24 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41 |
WO2010003219A1 (en) * | 2008-06-17 | 2010-01-14 | Universite Laval | Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines |
WO2012084951A1 (en) * | 2010-12-22 | 2012-06-28 | Bayer Animal Health Gmbh | Enhanced immune response in bovine species |
KR101323845B1 (ko) * | 2011-01-21 | 2013-10-31 | 광주과학기술원 | 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물 |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
IL286537B (en) * | 2013-03-15 | 2022-07-01 | In3Bio Ltd | Synthetic proteins that assemble themselves |
CU24299B1 (es) * | 2013-08-02 | 2017-12-08 | Centro De Inmunología Molecular | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico |
HK1194912A2 (en) * | 2013-09-17 | 2014-10-24 | Bestop Group Holdings Ltd | Growth factor concentrate and the use thereof |
US10105306B2 (en) * | 2013-09-17 | 2018-10-23 | Bestop Group Holdings Limited | Method of preparing a growth factor concentrate |
WO2015135942A1 (en) * | 2014-03-11 | 2015-09-17 | Universite D'aix-Marseille | A chimeric peptide that interacts with cell membrane gangliosides |
WO2018166542A1 (es) | 2017-03-15 | 2018-09-20 | Centro De Inmunologia Molecular | Método para el tratamiento de pacientes con carcinomas |
US12019073B2 (en) * | 2017-03-15 | 2024-06-25 | Centro De Inmunologia Molecular | Method for the treatment of patients with carcinomas |
CA3076012A1 (en) * | 2017-09-27 | 2019-04-04 | L2 Diagnostics, Llc | Erbb peptide pharmaceutical and vaccine compositions and therapeutics uses thereof for cancer |
CU24534B1 (es) * | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
CN109865137A (zh) * | 2019-01-23 | 2019-06-11 | 天德悦(北京)生物科技有限责任公司 | 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4857637A (en) * | 1986-05-07 | 1989-08-15 | Genentech, Inc. | Methods and compositions for immunologically modulating growth hormone receptor activity |
IT1206250B (it) * | 1987-02-18 | 1989-04-14 | Ist Farmacoterapico It Spa | Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla- |
US5726292A (en) * | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
WO1994001133A1 (en) | 1992-07-08 | 1994-01-20 | Schering Corporation | Use of gm-csf as a vaccine adjuvant |
DE69428763T2 (de) * | 1993-12-09 | 2002-08-01 | Ct De Inmunologia Molecular Ci | Monoklonale Antikörper gegen Ganglioside und deren Verwendung in der spezifischen, aktiven Immuntherapie gegen bösartige Tumoren |
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
WO1999036085A1 (en) * | 1998-01-16 | 1999-07-22 | Biomira Usa Inc. | Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes |
-
2001
- 2001-11-29 PE PE2001001202A patent/PE20020572A1/es not_active Application Discontinuation
- 2001-12-05 AR ARP010105662A patent/AR031638A1/es not_active Application Discontinuation
- 2001-12-06 AU AU2151902A patent/AU2151902A/xx active Pending
- 2001-12-06 JP JP2002547529A patent/JP4210519B2/ja not_active Expired - Lifetime
- 2001-12-06 DK DK01999387.2T patent/DK1356822T3/da active
- 2001-12-06 AT AT01999387T patent/ATE485833T1/de active
- 2001-12-06 EA EA200300640A patent/EA005138B1/ru not_active IP Right Cessation
- 2001-12-06 MX MXPA03005032A patent/MXPA03005032A/es active IP Right Grant
- 2001-12-06 EP EP01999387A patent/EP1356822B1/en not_active Expired - Lifetime
- 2001-12-06 UY UY27059A patent/UY27059A1/es unknown
- 2001-12-06 DE DE60143363T patent/DE60143363D1/de not_active Expired - Lifetime
- 2001-12-06 US US10/003,463 patent/US7776342B2/en active Active
- 2001-12-06 KR KR1020037007634A patent/KR100850473B1/ko active IP Right Grant
- 2001-12-06 CN CNB018215602A patent/CN1291755C/zh not_active Expired - Lifetime
- 2001-12-06 CA CA2431188A patent/CA2431188C/en not_active Expired - Lifetime
- 2001-12-06 BR BR0116013-3 patent/BRPI0116013B8/pt not_active IP Right Cessation
- 2001-12-06 WO PCT/CU2001/000010 patent/WO2002045746A2/es active IP Right Grant
- 2001-12-06 AU AU2002221519A patent/AU2002221519B2/en not_active Expired
-
2003
- 2003-06-04 NZ NZ526282A patent/NZ526282A/en not_active IP Right Cessation
- 2003-06-05 ZA ZA200304411A patent/ZA200304411B/en unknown
-
2004
- 2004-08-30 HK HK04106497A patent/HK1063726A1/xx not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004523494A5 (ja) | ||
Hu et al. | Immunostimulating complexes (ISCOMs) for nasal vaccination | |
JP4137640B2 (ja) | 新規プロテオソーム−リポサッカリドワクチンアジュバント | |
Roozbehani et al. | Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection | |
Velikovsky et al. | Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used | |
CA2431188A1 (en) | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens | |
ES2311478T3 (es) | Composiciones de vacuna contra el hcv. | |
Cong et al. | Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice | |
JP2008530245A5 (ja) | ||
Gaspar et al. | Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines | |
Revaz et al. | Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice | |
Golshani et al. | Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen | |
KR20030015288A (ko) | 보조제 배합물로서의 큐에스-21 및 아이엘-12 | |
JP2013520487A (ja) | 免疫原性タンパク質および組成物 | |
Decker et al. | Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease | |
Simerska et al. | Oral vaccine delivery-new strategies and technologies | |
Wang et al. | Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A | |
ES2386369T3 (es) | Vacunas que comprenden la proteína de núcleo HBC truncado mas adyuvantes basados en saponina | |
US20040109871A1 (en) | M cell directed vaccines | |
US20180071384A1 (en) | Vaccines based on hepatitis b core antigens | |
Wu et al. | Construction and protective immunogenicity of DNA vaccine pNMB0315 against Neisseria meningitidis serogroup B | |
WO2009062454A2 (en) | Universal vaccine for the treatment and prophylaxis of lyme disease for human and veterinary use and method of its manufacture | |
Tao et al. | Immune responses induced by a combined vaccination with a recombinant chimera of Mycoplasma hyopneumoniae antigens and capsid virus-like particles of porcine circovirus type 2 | |
Menon et al. | Mycobacterial ESAT-6 protein enhances mouse IFN-γ responses to Mycoplasma hyopneumoniae P71 protein | |
BRPI0416178A (pt) | método de incorporação de antìgeno em vesìculas de membrana externa de bactérias neisseria e formulações de vacina resultantes |